aleksandar-mijatovic-shutterstock-com

Aleksandar Mijatovic / Shutterstock.com

18 August 2015Americas

Pfizer’s Hospira buyout approved in Australia and Canada

Pfizer’s $17 billion buyout of Hospira has been approved in Canada and Australia after the countries’ competition bureaus approved the deal.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

US and Brazil clear path for Pfizer’s Hospira buyout

26 August 2015 Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval.

European Commission approves Pfizer’s buyout of Hospira

6 August 2015 The European Commission has approved US pharmaceutical company Pfizer’s $17 billion acquisition of Hospira, a move that will see Pfizer acquire the drugs company’s biosimilar portfolio.

More on this story

US and Brazil clear path for Pfizer’s Hospira buyout

26 August 2015 Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval.

European Commission approves Pfizer’s buyout of Hospira

6 August 2015 The European Commission has approved US pharmaceutical company Pfizer’s $17 billion acquisition of Hospira, a move that will see Pfizer acquire the drugs company’s biosimilar portfolio.

More on this story

US and Brazil clear path for Pfizer’s Hospira buyout

26 August 2015 Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval.

European Commission approves Pfizer’s buyout of Hospira

6 August 2015 The European Commission has approved US pharmaceutical company Pfizer’s $17 billion acquisition of Hospira, a move that will see Pfizer acquire the drugs company’s biosimilar portfolio.

More features

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’

Powell Gilbert launches Düsseldorf office with leading patent litigator

Startups toolkit: Why investors want more than patents

J&J fends off generic schizophrenia drug bids

Kilpatrick adds ‘seasoned litigator’ as trademark partner

WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond

Startup challenges rival over brain monitoring tech at ITC

UKIPO rejects Boehringer’s SPC for horse inhaler